Gilead Sciences, Inc. $GILD Shares Purchased by Sowell Financial Services LLC

Sowell Financial Services LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,373 shares of the biopharmaceutical company’s stock after purchasing an additional 5,573 shares during the quarter. Sowell Financial Services LLC’s holdings in Gilead Sciences were worth $1,764,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GILD. Corundum Trust Company INC acquired a new position in Gilead Sciences in the 3rd quarter valued at $26,000. MTM Investment Management LLC grew its stake in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares in the last quarter. Millstone Evans Group LLC raised its holdings in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 118 shares during the last quarter. Y.D. More Investments Ltd acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $37,000. Finally, Board of the Pension Protection Fund acquired a new stake in Gilead Sciences in the 4th quarter valued at about $37,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $138.80 on Wednesday. The firm has a 50 day simple moving average of $145.10 and a 200-day simple moving average of $130.01. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The stock has a market cap of $172.28 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 1.83 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the company posted $1.90 EPS. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GILD. Wolfe Research increased their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective for the company. Daiwa Securities Group upped their target price on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, TD Cowen upped their target price on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $157.81.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition strengthens oncology pipeline: Gilead agreed to acquire Tubulis for up to $5.0B ($3.15B upfront, up to $1.85B in milestones), adding a next‑generation ADC platform and lead candidate TUB‑040 (Phase 1b/2 for platinum‑resistant ovarian cancer and NSCLC). The transaction is expected to close in Q2 2026 and Tubulis will operate inside Gilead post‑close — a tangible pipeline boost that can extend future oncology revenue. Business Wire
• Positive Sentiment: Analyst support: Bernstein put a Buy on Gilead, signaling conviction that recent M&A and pipeline moves improve medium‑term prospects — a positive endorsement that can underpin investor confidence. Globe and Mail
• Neutral Sentiment: Street reactions are mixed: Some banks raised price targets (RBC nudged its target higher to $123) but maintained conservative ratings, leaving implied upside limited from some analysts’ perspectives. That keeps expectations calibrated even as the company spends on deals. MarketScreener
• Neutral Sentiment: Macro/sector context: Broad market weakness today and healthcare sector headlines (Medicare rate moves, sector M&A activity) are weighing on stocks generally; Gilead’s move is part of a wider Q1 surge in pharma M&A. Yahoo / Sector roundup
• Negative Sentiment: Execution and strategy concerns: Commentary frames recent M&A as partly defensive — “more about survival” — and investors may be worried about integration risk, high upfront cost and contingent milestones. These concerns can pressure the share price in the short term despite long‑term pipeline logic. Moby / Yahoo

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.